FDA OKs Ozempic for diabetic kidney disease

The FDA has approved Ozempic to reduce the risk of kidney disease worsening, kidney failure and cardiovascular-related death in adults with Type 2 diabetes and chronic kidney disease. 

This new approval expands Ozempic's use, adding to its previous indications for improving glycemic control in Type 2 diabetes and reducing major cardiovascular events in people with heart disease, according to a Jan. 28 news release from Novo Nordisk. 

The basis of the approval was due to a phase 3 trial that demonstrated the drug significantly reduced the risk of kidney disease progression and cardiovascular death by 24%, compared to a placebo, over three years. 

Ozempic was first approved by the FDA in 2017 for blood sugar control in Type 2 diabetes. It received a cardiovascular indication in 2020 and is now the most broadly indicated GLP-1 receptor agonist for managing diabetes, kidney disease and heart risk.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like